17767856. ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS simplified abstract (Arizona Board of Regents on Behalf of Arizona State University)
Contents
- 1 ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 How does this technology compare to other viral vectors used in cancer therapy?
- 1.11 What are the potential long-term effects of using Myxoma viruses in cancer therapy?
- 1.12 Original Abstract Submitted
ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS
Organization Name
Arizona Board of Regents on Behalf of Arizona State University
Inventor(s)
Douglas Grant Mcfadden of Tempe AZ (US)
Lino Torres-dominguez of Tempe AZ (US)
Mohammed Masmudur Rahman of Chandler AZ (US)
ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS - A simplified explanation of the abstract
This abstract first appeared for US patent application 17767856 titled 'ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS
Simplified Explanation
The patent application describes Myxoma viruses that express multi-specific immune cell engagers for inhibiting and treating hematological cancer in a subject. It also includes the use of leukocytes containing Myxoma virus for the same purpose.
- Myxoma viruses engineered to express multi-specific immune cell engagers such as BiKE, BiTE, and/or MiTE.
- Leukocytes containing Myxoma virus that can be used to inhibit and treat hematological cancer in a subject.
Potential Applications
The technology can be applied in the field of cancer immunotherapy for the treatment of hematological cancers such as leukemia and lymphoma.
Problems Solved
This technology provides a novel approach to targeting and killing cancer cells specifically, potentially reducing the side effects associated with traditional cancer treatments.
Benefits
- Targeted treatment of hematological cancers - Potential for reduced side effects compared to traditional treatments - Utilizes the body's immune system to fight cancer
Potential Commercial Applications
The technology could be licensed to pharmaceutical companies for the development of new cancer therapies. It may also be used in research institutions for further studies on cancer immunotherapy.
Possible Prior Art
Prior art may include other viral vectors used in cancer therapy, such as oncolytic viruses or gene therapy vectors.
Unanswered Questions
How does this technology compare to other viral vectors used in cancer therapy?
This article does not provide a direct comparison to other viral vectors used in cancer therapy, such as oncolytic viruses or gene therapy vectors. Further research may be needed to determine the advantages and disadvantages of using Myxoma viruses for this purpose.
What are the potential long-term effects of using Myxoma viruses in cancer therapy?
The article does not address the potential long-term effects of using Myxoma viruses in cancer therapy. Future studies may be necessary to evaluate the safety and efficacy of this approach over extended periods of time.
Original Abstract Submitted
The disclosure provides Myxoma viruses that express one or more multi-specific immune cell engagers, such as BiKE, BiTE and/or MiTE and their use in inhibiting and/or treating a hematological cancer in a subject. The disclosure also provides a leukocyte having a Myxoma virus that expresses one or more multi-specific immune cell engagers, and the use of the leukocyte for inhibiting and/or treating a hematological cancer in a subject.
